Viewing Study NCT03703050

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:04 PM
Ignite Modification Date: 2026-02-25 @ 7:27 PM
Study NCT ID: NCT03703050
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-29
First Post: 2018-10-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma View
Keywords: